Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Niacinamide Brightening Toner is a topical skincare product developed by Good Molecules to address uneven skin tone, dullness, and visible pores. The formulation features a combination of active ingredients including niacinamide (vitamin B3), arbutin, licorice root extract, and 3-O-ethyl ascorbic acid (a stable vitamin C derivative). Niacinamide works by inhibiting the transfer of melanosomes from melanocytes to keratinocytes, while arbutin and licorice root extract act as tyrosinase inhibitors to reduce melanin synthesis. In clinical research, specifically a Phase 3 study (NCT05486130), the toner was evaluated as an adjunctive treatment used in combination with prescription-strength 4% hydroquinone to improve the appearance of facial hyperpigmentation and melasma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Niacinamide Brightening Toner.